JP2024516633A5 - - Google Patents
Info
- Publication number
- JP2024516633A5 JP2024516633A5 JP2023565387A JP2023565387A JP2024516633A5 JP 2024516633 A5 JP2024516633 A5 JP 2024516633A5 JP 2023565387 A JP2023565387 A JP 2023565387A JP 2023565387 A JP2023565387 A JP 2023565387A JP 2024516633 A5 JP2024516633 A5 JP 2024516633A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- alkylene
- group
- alkyl
- halogens
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163179616P | 2021-04-26 | 2021-04-26 | |
| US63/179,616 | 2021-04-26 | ||
| PCT/US2022/026144 WO2022232025A1 (en) | 2021-04-26 | 2022-04-25 | Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024516633A JP2024516633A (ja) | 2024-04-16 |
| JP2024516633A5 true JP2024516633A5 (enExample) | 2024-11-27 |
Family
ID=81750587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023565387A Pending JP2024516633A (ja) | 2021-04-26 | 2022-04-25 | オレキシン－２受容体アゴニスト活性を有する置換されるアミド大環状化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240124485A1 (enExample) |
| EP (1) | EP4329877B1 (enExample) |
| JP (1) | JP2024516633A (enExample) |
| CN (1) | CN117440955A (enExample) |
| AU (1) | AU2022267220A1 (enExample) |
| CA (1) | CA3215210A1 (enExample) |
| ES (1) | ES3062687T3 (enExample) |
| WO (1) | WO2022232025A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4622712A1 (en) * | 2022-11-23 | 2025-10-01 | Vertex Pharmaceuticals Incorporated | Substituted macrocyclic amine modulators of orexin receptor 2 |
| EP4658660A1 (en) | 2023-01-31 | 2025-12-10 | Jazz Pharmaceuticals Ireland Limited | Macrocyclic orexin receptor agonists and uses thereof |
| KR20250155550A (ko) | 2023-03-16 | 2025-10-30 | 다케다 야쿠힌 고교 가부시키가이샤 | 매크로시클릭 헤테로시클 화합물 및 이의 용도 |
| US20240425521A1 (en) | 2023-06-01 | 2024-12-26 | H. Lundbeck A/S | Spiromacrocyclic orexin 2 receptor agonists |
| WO2025096445A1 (en) | 2023-10-30 | 2025-05-08 | Alkermes, Inc. | Synthesis of intermediates for the preparation of macrocyclic compounds |
| WO2025124698A1 (en) | 2023-12-12 | 2025-06-19 | Idorsia Pharmaceuticals Ltd | Aryl sulfone and sulfanone derivatives as orexin receptor modulators |
| TW202542165A (zh) | 2023-12-19 | 2025-11-01 | 瑞士商愛杜西亞製藥有限公司 | 大環食慾素激動劑 |
| WO2026017128A1 (zh) * | 2024-07-17 | 2026-01-22 | 江苏恩华药业股份有限公司 | 作为食欲素受体激动剂的环烯烃衍生物及其组合物和用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA01011018A (es) * | 1999-04-30 | 2002-05-06 | Pfizer Prod Inc | Moduladores del receptor glucocorticoide. |
| EP2038255A2 (en) * | 2006-06-16 | 2009-03-25 | High Point Pharmaceuticals, LLC | Pharmaceutical use of substituted piperidine carboxamides |
| US8258163B2 (en) | 2008-06-04 | 2012-09-04 | Board Of Regents, The University Of Texas System | Small-molecule agonists for type-2 orexin receptor |
| MX2011004551A (es) * | 2008-10-30 | 2011-05-25 | Merck Sharp & Dohme | Antagonistas del receptor de orexina de isonicotinamida. |
| KR20110096557A (ko) * | 2008-12-10 | 2011-08-30 | 아칠리온 파르마세우티칼스 인코포레이티드 | 바이러스 복제의 억제제로서 4-아미노-4-옥소부타노일 펩티드 사이클릭 유사체 |
| WO2014198880A1 (en) | 2013-06-14 | 2014-12-18 | Ferrer Internacional, S.A. | 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity |
| US20160250224A1 (en) | 2013-09-24 | 2016-09-01 | The Board Of Regents Of The University Of Texas System | Orexin-control of bone formation and loss |
| CA2930693A1 (en) | 2013-11-15 | 2015-05-21 | The Board Of Trustees Of The Leland Stanford Junior Unversity | Methods of treating heart failure with agonists of hypocretin receptor 2 |
| PE20161064A1 (es) | 2013-12-12 | 2016-10-28 | Univ Tsukuba | Derivado de sulfonamida o sales de adicion de acido farmaceuticamente aceptables del mismo |
| WO2015147240A1 (ja) | 2014-03-28 | 2015-10-01 | 国立大学法人筑波大学 | 敗血症の予防治療剤 |
| PL3411358T3 (pl) | 2016-02-04 | 2022-02-28 | Takeda Pharmaceutical Company Limited | Podstawiony związek piperydynowy i jego zastosowanie |
| WO2018164191A1 (ja) * | 2017-03-08 | 2018-09-13 | 武田薬品工業株式会社 | 置換ピロリジン化合物およびその用途 |
| US20200207734A1 (en) | 2017-08-03 | 2020-07-02 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| EA202192934A1 (ru) * | 2017-12-25 | 2022-02-09 | Такеда Фармасьютикал Компани Лимитед | Гетероциклическое соединение и его применение |
| US12077522B2 (en) * | 2018-06-29 | 2024-09-03 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and application thereof |
| WO2021026047A1 (en) * | 2019-08-08 | 2021-02-11 | Merck Sharp & Dohme Corp. | Heteroaryl pyrrolidine and piperidine orexin receptor agonists |
| FI4065585T3 (fi) * | 2019-11-25 | 2025-09-26 | Alkermes Inc | Substituoituja makrosyklisiä yhdisteitä ja niihin liittyviä hoitomenetelmiä |
| US12006330B2 (en) * | 2020-12-21 | 2024-06-11 | Alkermes, Inc. | Substituted macrocyclic compounds and related methods of treatment |
-
2022
- 2022-04-25 WO PCT/US2022/026144 patent/WO2022232025A1/en not_active Ceased
- 2022-04-25 EP EP22724964.6A patent/EP4329877B1/en active Active
- 2022-04-25 CA CA3215210A patent/CA3215210A1/en active Pending
- 2022-04-25 CN CN202280038386.8A patent/CN117440955A/zh active Pending
- 2022-04-25 JP JP2023565387A patent/JP2024516633A/ja active Pending
- 2022-04-25 ES ES22724964T patent/ES3062687T3/es active Active
- 2022-04-25 AU AU2022267220A patent/AU2022267220A1/en active Pending
-
2023
- 2023-10-03 US US18/376,020 patent/US20240124485A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024516633A5 (enExample) | ||
| JP2024501641A5 (enExample) | ||
| JP2023502441A5 (enExample) | ||
| JP2023500328A5 (enExample) | ||
| JP2024520396A5 (enExample) | ||
| JP2023554282A5 (enExample) | ||
| IL304986A (en) | Compositions and methods for inhibition of ras | |
| JP2022545359A5 (enExample) | ||
| JP2024520395A5 (enExample) | ||
| JP2021535112A5 (enExample) | ||
| JP2010510999A5 (enExample) | ||
| JP2022510313A5 (enExample) | ||
| JP2021513967A5 (enExample) | ||
| JP2014500295A5 (enExample) | ||
| JP2006504766A5 (enExample) | ||
| JP2021523159A5 (enExample) | ||
| RU2012116877A (ru) | Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы | |
| JP2024001048A5 (enExample) | ||
| JP2001526269A5 (enExample) | ||
| RU2013143028A (ru) | Тиазолилфенилбензолсульфонамидопроизводные в качестве ингибиторов киназ | |
| JP2020533352A5 (enExample) | ||
| JP2023522177A5 (enExample) | ||
| JP2016503414A5 (enExample) | ||
| JPWO2021060453A5 (enExample) | ||
| JP2023553428A5 (enExample) |